Evusheld - Health Technology Assessment

Published on: 19 October 2022

A summary of our submission to the National Institute for Health Care and Excellence (NICE) for Evusheld.

On 19 October 2022, we submitted to the National Institute for Healthcare and Excellence (NICE)’s Health Technology Assessment (HTA) for Evusheld.

Evusheld is a pre-exposure prophylaxis treatment (this means a treatment given to people before being exposed to the risk of COVID-19 infection in order to prevent disease). Current COVID-19 treatments offered are given to people after they have been exposed to COVID-19. The government made a decision over the summer not to purchase the drug and instead refer it to NICE for assessment.

As a patient organisation, we have used evidence from people affected by lymphoma to form our submission to the NICE assessment. In the submission we have outlined:

  • The impact that shielding has had on people affected by lymphoma, including caregivers and family
  • How the pandemic continues to impact the lives of those who may not have mounted a response to vaccines despite the rest of the UK returning to ‘normal’
  • What the advantages and disadvantages of Evusheld are, including how it would allow those who are immunocompromised to live more freely and potentially reduce admissions to hospital and burden on the NHS
  • Additional global evidence that outlines the benefits of Evusheld, referencing research from countries where Evusheld has already been approved for use

We hope that this evidence enables the government to understand the importance of considering purchasing the drug for use on the NHS as soon as possible.

In the meantime, please continue to be safe, particularly as we approach winter. We understand that COVID-19 remains a concern for people affected by lymphoma. There are ways you can continue to stay safe and reduce your risks of catching COVID which we summarise here.

Published: 19 October 2022